LONDON, UK (GlobalData), 24 May 2012 - Tourists may represent the biggest at-risk group for contracting hepatitis A, according to new findings released by pharmaceuticals intelligence provider GlobalData.
The new report* indicates that, to combat this, vaccinations are expected to become more common in correlation with an increase in global travel, which is introducing individuals to geographic areas with a higher risk of HAV infection. Market growth for HAV vaccines has been only moderate in recent years due to a lack of awareness or symptoms, and the fact that vaccination is not mandatory in most countries. However, following cases such as the epidemic of HAV in Puglia, southern Italy, in 1998, the use of hepatitis A preventive vaccines rose dramatically among adolescents and toddlers.
Future increases in vaccination coverage for hepatitis A will rely on awareness programs about viral hepatitis by bodies such as Sistema Epidemiologico Integrato dell’Epatite Virale Acuta (SEIEVA) in Europe, and the Centers for Disease Control and Prevention (CDC) in the US.
The available vaccines for HAV are already very successful, boasting a high efficacy of almost 90% and displaying a high safety profile, with less than 1% of patients suffering serious adverse events. As a result, little scope is left to tempt new drug entrants in the near future and no novel vaccines are expected to emerge in the near future. However, opportunity lies in the development of an oral hepatitis A vaccine which could be available in single doses, as currently many people fail to take their additional second “booster” vaccine.
HAV is an acute infectious disease of the liver, transmitted person-to-person by the ingestion of contaminated food or water, or through direct contact with an infectious person. Hepatitus is often asymptomatic in young children, but adults often suffer symptoms including fatigue, fever, nauseau, and abdominal pain. Exposure to HAV does not cause chronic infection or liver disease, but very rare cases of acute liver failure have resulted from HAV infections.
GlobalData’s analysis shows that the global hepatitis A preventive vaccines market stood at $874.8m in 2006 and grew at a compound annual growth rate (CAGR) of 7.3% to reach $1,245.4m in 2011. GlobalData forecasts that the global hepatitis A preventive vaccines market will grow at a CAGR of 4.8% over the next eight years to reach $1,805.8m by 2019, helped along by awareness campaigns boosting the vaccine market in developed economies.
*Hepatitis A Vaccine - Pipeline Assessment and Market Forecasts to 2019
This report is an essential source of information and analysis on the global hepatitis A preventive vaccines market. It identifies the key trends shaping and driving the global hepatitis A preventive vaccines market, and provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis A preventive vaccines market sector.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
-ABOUT GLOBALDATA-
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@globaldata.com.
